A Comparison Of 1995 WHO Classification With 2003 ISN/Rpsclassification Of Lupus Nephritis: A Single Centre Observation

Background: In the past, lupus nephritis was histologically classified according to the 1995 WHO Classification. With the introduction of the 2003 ISN/RPS Classification, many nephropathology services converted to this new classification. This study was undertaken to compare both classification systems in a single centre practice. Methods: 103 consecutive adequate renal biopsies initially reported as lupus nephritis in the Department of Pathology, Faculty of Medicine, University of Malaya were reassessed using the criteria of both the 1995 WHO Classification and the 2003 ISN/ RPS Classification. Results: The relative prevalence for each class using the WHO Classification were: Class I (1%), Class II (8.7%), Class III (6.8%), Class IV (60.2%), Class V (20.4%), Class VI (2.9%) while the prevalence using the 2003 ISN/RPS Classification were: Class I (1%), Class II (8.7%), Class III (6.8%), Class IV (61.2%), Class V (21.3%), Class VI (1%). Both classifications were essentially comparable with regards to Classes I, II and III. The differences in Classes IV, V and VI were significant in potential to alter patient management. The identification of segmental lesions (Class IV-S) over and above a global nephritis (Class IV-G) deserves more focused clinicopathological studies to gauge whether these groups have different clinical manifestations and outcomes. With regards Class V, the ISN/RPS system, by requiring that all mixed classes be stipulated in the diagnostic line, minimizes the chances of patients missing out on additional treatment. The ISN/ RPS system has stricter criteria for Class VI, which again minimizes patients missing out on therapy. On the whole, the ISN/RPS system is more user-friendly as criteria are more clearly defined which translates to more benefits to patient care.

The New Classification Criteria of Systemic Lupus Erythematosus / 대한내과학회지

Systemic lupus erythematosus (SLE) is a prototype for multi-system, autoimmune diseases of unknown etiology, characterized by the production of autoantibodies. SLE can involve any organ system of the body with constitutional symptoms, including musculoskeletal, skin, renal, neuropsychiatric, cardiovascular, respiratory and gastrointestinal systems. These wide spectra of disease manifestations have made disease classification difficult. American College of Rheumatology (ACR) proposed classification criteria for SLE for research purpose in 1982, which had been widely used for research purpose and not for diagnosis. In 1997, these criteria were updated with further recognition of antiphospholipid antibodies, but not validated. But ACR criteria didn't still meet the necessity for earlier diagnosis of SLE. In order to improve clinical relevance and incorporate new knowledge to the field of lupus immunology, the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC), an international lupus expert group dedicated to clinical research on lupus, revised the ACR systemic lupus classification criteria in 2012. The new 2012 SLICC criteria were validated using a large set of patient scenarios rated by experts. The history and diagnostic utility of SLE criteria are covered in this review.

Anesthetic and Postoperative Intensive Care for Patient with Systemic Lupus Erythematosis and Antiphospholipid Syndrome: A Case Report / 대한구급학회지

The antiphospholipid syndrome (APS) is characterized by vascular thrombosis despite of prolongation of coagulation profile in laboratory findings and pregnancy morbidity in the presence of antiphospholipid antibody. It occurs primarily or secondarily to autoimmune disease. This case report concerns a pelviscopic left ovarian cystectomy in a 32-year-old female with APS and systemic lupus erythematosis. To manage the hypercoagulability, oral warfarin and low molecular weight haparin were given pre- and postoperatively. In perioperative period, we monitored activated clotting time to prevent intraoperative thrombosis and tried to avoid dehydration, hypothermia and infection.

Thiopurine S-methyltransferase Polymorphisms and the Relationship between the Mutant Alleles and the Adverse Effects in Systemic Lupus Erythematosus Patients Taking Azathioprine / 대한류마티스학회지

OBJECTIVES: To elucidate the genetic basis for Thiopurine methyltransferase (TPMT) polymorphism and investigate the relationship between TPMT mutant and the adverse effect in patients with systemic lupus erythematosis (SLE) taking azathioprine (AZA) in Korea. METHODS: The TPMT genotype was determined in two hundred healthy adults and 342 patients with SLE by MALDI-TOF and correlated with the effects of clinical exposure to AZA. RESUTLS: TPMT polymorphism were detected in 2/200 healthy adults (1%), which were heterozygotes with TPMT*3C and TPMT*6 allele, respectively, and 17/342 (4.97%), which were 12 heterozygotes with TPMT*3C and 5 heterozygotes with TPMT*6 allele, respectively, which had a higher frequency of TPMT mutant alleles compared to the healthy controls (p=0.015). Severe nausea occurred in 4 patient with TPMT*3C allele, and severe bone marrow toxicity in a patient with TPMT*6 allele taking AZA. Twenty three in 94 (24.47%) SLE patients taking AZA were suspicious of the adverse effects such as leucopenia (n=17), nausea (n=4) and abnormal liver function test (n=1). AZA was relatively well tolerated among the rest of them. CONCLUSION: The heterozygote with TPMT*3C and *6 were frequently detected in the patient with SLE compared to healthy adults and there was no statistical correlation between TPMT genotype and AZA toxicity. TMPT genotyping cannot replace regular blood monitoring in SLE patients on AZA treatment.